Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. *Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.* 

# Prevalence, Risk Factors and Awareness about HCV Infection in Pregnant Women in a Tertiary Care Center in North India

Dr. Pavika Lal

Received: 10 December 2019 Accepted: 31 December 2019 Published: 15 January 2020

#### 6 Abstract

7 Among the viral infections affecting the liver in pregnancy, Hepatitis C though uncommon

- <sup>8</sup> now is recognized to be a serious global public health problem affecting 170 million people
- 9 worldwide I .e. 3

10

3

4

Index terms— Introduction-Among the viral infections affecting the liver in pregnancy, Hepatitis C though uncommon now 11 12 is recognized to be a serious global public health problem affecting 170 million people worldwide I .e. 3% of the 13 population [1]. The prevalence of anti-HCV antibody in pregnant women in developed countries ranges from 14 0.14 to 4.4 %, whereas the seroprevalence in Indian pregnant female population is 1.03 % [2,3,4]. Following the 15 decreasing transmission of HCV by blood -transfusion, intravenous drug use has now become the primary route 16 of new HCV infections in adults while mother to child transmission (MTCT) is the major route of new infections 17 in young children in the developed as well as in developing countries. [5] Approximately 7-8 % of hepatitis 18 C virus-positive women transmit this virus to their offspring [6] mainly because they are ignorant about this 19 infection and unaware of their status. The natural course of hepatitis C is a progression from acute hepatitis to 20 chronic hepatitis, which occurs in 55%-85 % of patients. 21

## 22 1 Introduction

mong the viral infections affecting the liver in pregnancy, Hepatitis C though uncommon now is recognized to be a serious global public health problem affecting 170 million people worldwide I .e. 3% of the population [1]. The prevalence of anti-HCV antibody in pregnant women in developed countries ranges from 0.14 to 4.4 %, whereas the seroprevalence in Indian pregnant female population is 1.03 % [2,3,4].

Following the decreasing transmission of HCV by blood -transfusion, intravenous drug use has now become the primary route of new HCV infections in adults while mother to child transmission (MTCT) is the major route of new infections in young children in the developed as well as in developing countries. [5] Approximately 7-8 % of hepatitis C virus-positive women transmit this virus to their offspring [6] mainly because they are ignorant about this infection and unaware of their status. The natural course of hepatitis C is a progression from acute

 $_{32}$  hepatitis to chronic hepatitis, which occurs in 55%-85 % of patients.

Hepatitis C infection leads to chronic liver disease, cirrhosis as well as known to cause hepatocellular carcinoma.

Still World Health Organization (WHO) do not recommend the universal screening of Hepatitis B and C in pregnant women, although testing of HIV is mandatory after proper voluntary counseling. The study was undertaken with the aim to assess the exclusive seroprevalence of Hepatitis C infection in pregnant females and

<sup>37</sup> to know the risk factors, their attitude, and awareness against this dreadful disease.

## 38 **2** II.

## <sup>39</sup> 3 Material and Methods

This was a prospective observational study done at our tertiary care center in the obstetrics and gynecology department of UISEMH,GSVM Medical College in Kanpur(India) from November 2017 to August 2019.After taking a proper written informed consent, all antenatal women attending the OPD and in emergency who were exclusively HCV positive were included in the study group. Age, Parity, Gestational age-matched women delivering during the same time frame who were tested negative for HCV were taken as controls. The initially 45 reactive samples were re-tested and considered ELISA positive if both results were reactive. Once hepatitis C
46 was diagnosed, a qualitative HCV RNA test was done to determine the baseline viral load by RNA PCR. A

structured questionnaire was prepared comprising of questions and a face to face interview was done to know the
 awareness of viral infections during the antenatal period.

Those previously diagnosed to have some chronic liver disease, Intrahepatic cholestasis of pregnancy, or coinfection with HIV and Hepatitis B were excluded from the study. Laboratory tests to evaluate the extent of liver disease were done, including the following: Bilirubin, ALT, AST, albumin, platelet count, and prothrombin time. A total of 5853 antenatal patients had reported during the study period, out of which 126 were found to

<sup>53</sup> be HCV positive. The patients were further advised for HCV RNA, but only 98 had opted for HCV RNA.

54 Statistical Analysis-Data was analyzed using SPSS 22.0.Categorical variables were analyzed using the Odds 55 ratio (OD), and the Chi-square test & p-value <0.05 were considered significant. The study has been approved 56 by the Ethics Committee of GSVM Medical College, Kanpur.

## 57 **4 III.**

#### 58 5 Results

One hundred twenty-six (2.15 %) of the 5853 pregnant women tested positive for anti HCV antibodies. Of these, 72 (73.4%) were positive for HCV RNA by RT -PCR. Most of the HCV reactive obstetric patients were in the reproductive age group and the mean age was 26. years. Slightly higher rate of infection was found among women living in rural areas, which was 58.7% while that in the urban area was 41.2%. Both study and control groups

<sup>63</sup> had similar educational qualifications. (Table 1)

Most patients in the study group belonged to lower socioeconomic status. In the HCV infected group, 44.4 % patients belonged to lower socioeconomic status, while only 26.9% were of upper socioeconomic status. 46.8% were diagnosed in the intrapartum period, while only 38% were diagnosed during their antenatal visits among the

<sup>67</sup> risk factors for HCV infection previous history of blood transfusions, dilatation and curettage, previous surgery

 $_{68}$  were studied as independent risk factors (Table 2). The majority, 52.7% of the RNA positive patients and 46.1 %

<sup>69</sup> in RNA negative had a history of any surgery (Table 3). Of the 126 HCV positive patients, 22% did not have any

identifiable risk factors. Of the 5853 patients questioned, maximum awareness was about HIV and least about
 HCV (Table 4).

#### 72 6 Discussion

73 Our study represents a single hospital-based report to define the seroprevalence, risk factors, and knowledge 74 of hepatitis C infection in our patient population of pregnant women which usually caters to Kanpur and it's 75 adjoining areas (Kanpur-Dehat).

The study also found a higher rate of infection among women living in rural areas, with higher parity and 76 those belonging to rural areas. Higher infection rates among rural residents may be partially explained by the 77 higher prevalence of anemia among rural women. Leiken et al. have reported a higher mean parity of HCV 78 positive patients in their study [10]. They might be at increased risk because of their past pregnancies, hospital 79 admissions, past surgeries, obstetrical procedures, and blood transfusions. It was found that 73.4% of the anti-80 HCV antibody-positive pregnant women had detectable HCV RNA in their blood, a figure that is similar to 81 that found in most of the studies. [15][16][17] We found no significant association with maternal and neonatal 82 morbidity, but there are few studies which reveal increased risk of obstetric complications, but they had a few 83 sample size, which 84

#### 85 7 HIV

The prevalence of Hepatitis C positive pregnant women was found to be 2.15 % in our study, which is almost double the reported prevalence of 1.03% in a study from North India by Kumar A et al. [7] and similar to the findings of other epidemiologic studies [3,11]. Prevalence in western countries ranges from 0.14 to 4.4% due to more awareness towards one's health, education and better health care facilities [2,3]. The highest prevalence of infection occurs among the individuals of the reproductive age group 25-35 years because this is the peak age group and also at the same time explains the increased chances of exposure of these group of women to risk for the same time explains the increased chances of exposure of these group of women to risk

factors. [8,9,10]. 92 Earlier studies by ??ohman VR et al. have found an association between the prevalence of HCV and the known 93 94 risk factors of this infection [11]. In our study, history of D & C, surgery, and blood transfusion were found to be 95 major risk factors for transmission of HCV infection. Patients are exposed to unsterilized instrumentation where 96 D&C is done by paramedical staff without maintaining aseptic conditions .Also in a study by ??utin Y et al., it has been reported that in resource poor countries, the risk of iatrogenic HCV infection is high [12]. Intravenous 97 drug abuse is a significant risk factor in western countries [13]. In a study from Northern Italy, the principal risk 98 factors were a history of intravenous drug abuse (32%) and exposure to blood products (24%). 99 was inconclusive. In our study there was no significant variation in the level of liver enzymes Serum

was inconclusive. In our study there was no significant variation in the level of liver enzymes Serum transaminases and total bilirubin. This finding was similar to a study by Paternoster et al. [14] supporting the immune-mediated hypothesis.

In the present study, it was found that a substantial proportion of women with HCV had no evidence of 103 exposure to any known risk factors in their history, about 22% of patients did not have any identifiable risk 104 factor. This is comparable with the observation by Ward C et al. [15], that 40-73% of the women had no obvious 105 risk factors for HCV infection at the time of booking. It has been found that selective antenatal screening policy 106 based on risk factors, failed to identify over half of infected patients. [18] Routine antenatal HCV screening is not 107 mandatory in India, but identification of HCV in pregnant women is important because of their risk of long term 108 complications of infection, potential effects on pregnancy, and risk of transmission to their infants. Therefore 109 universal screening for HCV can be recommended. 110

111 V.

## 112 8 Conclusion

In our study, we found that there is high prevalence of Hepatitis C infection pregnant women posing a public health problem. Organizational bodies such as American College of Obstetricians and Gynecologists and Society for Maternal and Fetal medicine recommend selective antenatal screening solely based on high-risk factors which fail to identify over half of the infected patients, therefore universal screening in a pregnant female is justifiable and should be recommended to identify patients without any risk factors. Although it does not adversely affect the maternal or the neonatal outcome, but hepatitis C has long term ill effects on the health of both the mother and the child.

120 The need of the hour is to increase the awareness of hepatitis C infection by implementing educational programs

through mass media as presently done for HIV infection as well as by emphasis on preventive measures such as sterilization of instruments, screening blood and blood products and making services more accessible with

as sterilization of instruments, screening blood and blood products and making services more accessible with increasing utilization of antenatal services in rural areas.

1

	HCV POSITIVE( $N=126$ )		
	NUMBER	PERCENTAGE	
TOTAL	126	%	
AGE			
15-24 year	41	32.5	
25-35	80	63.5	
>35	05	3.9	
HABITAT			
Rural	74	58.7	
Urban	52	41.2	
PARITY			
Nullipara	27	21.4	
Multipara	99	78.5	
EDUCATION STATUS			
Illiterate	51	40.4	
Primary	58	46.0	
Secondary	17	13.49	

Figure 1: Table 1 :

# $\mathbf{2}$

	HCV Positive			
<b>Risk Factors</b>	(n=126) HCV RNA Posit	ive HCV	HCV Negative	p-value
		RNA	(n = 5727)	
	(n = 72) negat	tive $(n=26)$		
H/O Blood transfusion	16	9	456	$< 0.001^{*}$
	32%	40.9%	8.0%	
H/O Abortions	04	03	1125	$< 0.001^{*}$
	8%	13.6%	19.6%	
H/O multiple sex part-	03	02	25	$0.00001^{*}$
ners				
	4.1%	7.6%	0.43%	
H/O Episiotomy	24	12	3818	$0.00001^{*}$
	33.3	46.1	66.6	

Figure 2: Table 2 :

3

Risk factors	HCV Positive HCV RNA posi- tive	HCV RNA	$\begin{array}{l} \text{HCV}  \text{Negative} \\ (n=5727) \end{array}$	p value
H/O D&C	(n=72) 06 12%	(n=26) 04 18.2%	$987 \\ 17.2\%$	0.00603*
H/O Previous surgery	$egin{array}{c} 15 \ 30\% \end{array}$	$7\ 31.8\%$	$1007 \\ 17.6\%$	0.041*
H/O Dental procedure	$01 \\ 1.38\%$	00 00	$12 \\ 0.2\%$	0.168
H/O Amniocentesis	01 0.79%	$00 \\ 1.38\%$	$24 \\ 0.41\%$	0.523

Figure 3: Table 3 :

 $\mathbf{4}$ 

Figure 4: Table 4 :

- [Wasley et al. ()], A D Wasley, Epidemeology Altermj, C Of Hepatitis. Semin Liver Dis 2000. 20 p. .
- 125 [American college of obstetricians and gynecologists ACOG Educational Bulletin Viral hepatitis in pregnancy. Number (1998)]
- <sup>126</sup> 'American college of obstetricians and gynecologists'. *ACOG Educational Bulletin Viral hepatitis in pregnancy*.
- 127 Number July 1998. 1998. 248 p. . (Int J Gynaecol Obstet)
- [Centres for disease control and prevention, Recommendations for prevention and control of Hepatitis C virus (HCV) infection and 'Centres for disease control and prevention, Recommendations for prevention and control of Hepatitis C virus (HCV) infection and HCV related disease'. Morb Mortal Wkly Rep 1998. 47 p. .
- <sup>131</sup> [Saez et al. ()] 'Diagnostic and prognostic value of virologic tests in vertical transmission of hepatitis C virus <sup>132</sup> infection: results of a large prospective study in pregnant women'. A Saez , Losam , Loiaconoo , Lozanoc ,
- Alvareze, Pital. *Hepatogastroenterology* 2004. 51 p.
- [Leikin et al. ()] 'Epidemeological predictors of hepatitis C virus infection in pregnant women'. E L Leikin , J F
   Reinus , Schmell , N Tejani . ObstetGynecol 1994. 84 p. .
- 136
   [Baldo et al. ()] 'Epidemiology of HCV infection'. V Baldo , T Baldovin , R Trivello

   137
   10.2174/138161208784746770. Curr Pharm Des 2008. 14 p. .
- [Silverman et al. ()] 'Hepatitis C virus in pregnancy: seroprevalence and risk factors for infection'. N S Silverman
   B K Jenkin , C Wu . 10.1016/0002-9378(93)90627-U. Am J Obstet Gynecol 1993. 169 p. .
- [Arshad et al. ()] 'Hepatitis C virus infection during pregnancy and the newborn period are they opportunities
   for treatment'. M Arshad , S S El-Kamary , R Jhaveri . Journal of viral hepatitis 2011. 18 p. .
- I42 [Jabeen et al. ()] 'Pregnancy and pregnancy outcome in hepatitis C type 1b'. T Jabeen , Cannonb , J Hogan .
   I43 QJM 2000. 93 p. .
- [Pergam et al. ()] 'Pregnancy complications associated with hepatitis C: data from a 2003-2005 Washington state
  birth cohort'. S A Pergam , C C Wang , C M Gardella . 38.el- 38.e9. Am J Obstet Gynecol 2008. 199 (1) .
- [Kumar et al. ()] 'Prevalence & risk factors for hepatitis C virus among pregnant women'. A Kumar , K A Sharma
   , R K Gupta . Indian J Med Res 2007. 126 p. .
- [Kumar et al. ()] 'Prevalence & risk factors for hepatitis C virus among pregnant women'. A Kumar , K A Sharma
   , R K Gupta . Indian J Med Res 2007. 126 p. .
- [Conte et al. ()] 'Prevalence and clinical course of chronic hepatitis C virus infection and rate of HCV vertical
   transmission in a cohort of 15,250 pregnant women'. D Conte , Fraquellim , D Prati , A Colucci , E Minola .
   *Hepatology* 2000. 31 p. .
- [Ward et al. ()] 'Prevalence of hepatitis C among pregnant women attending an inner London obstetric
  department: uptake and acceptability of named antenatal testing'. C Ward , G Tudor-Williams , T Cotzias .
  10.1136/gut.47.2.277. Gut 2000. 47 (2) p. .
- <sup>156</sup> [Ward et al. ()] 'Prevalence of hepatitis C among pregnant women attending an inner London obstetric department: uptake and acceptability of named antenatal testing'. C Ward , Tudor Williams , G Cotziast ,
- <sup>158</sup> S Hargreaves, L Regan, Fostergr. *Gut* 2000. 47 p. .
- [Bohman et al. ()] 'Seroprevalence and risk factors for hepatitis C Virus in pregnant women'. V R Bohman ,
   Stettlerw , Littlebb , Wendelgd , Sutorlj , F G Cunningham . ObstetGynecol 1992. 80 p. .
- [Hutin and Hauria ()] 'Use of injections in healthcare settings worldwide, 000: literature review and regional
   estimates'. Y Hutin , Armstrongg Hauria . *BMJ* 2003. 327 p. .
- [Peternoster et al. ()] 'Viral load in HCV RNA-positive pregnant women'. D M Peternoster , C Santarossa , P
   Grella . Am J Gastroentrol 2001. 96 (9) p. .